BioNTech acquires Neon Therapeutics and NEO-PTC-01, a personalised neoantigen-targeted T cell therapy

BioNTech and Neon Therapeutics, Inc. announced that they have entered into a definitive merger agreement under which BioNTech will acquire Neon in an all-stock transaction valued at approximately $67.0 million. Neon is a biotechnology company developing novel neoantigen-based T cell therapies. Upon closing, it will operate as a subsidiary of BioNTech, a global clinical-stage biotechnology company focused on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The transaction will combine two organizations with a common culture of pioneering translational science and a shared vision for the future of cancer immunotherapy.Neon has deep expertise in the development of neoantigen therapies, with both vaccine and T-cell capabilities. Neon�s most advanced program is NEO-PTC-01, a personalized neoantigen-targeted T cell therapy candidate consisting of multiple T cell populations targeting the most therapeutically relevant neoantigens from each patient�s tumor.